Talk:Concerta

Hello, I work for McNeil Pediatrics, the company that makes Concerta(R), and I would like to provide a referenced, factual edit to the Concerta(R) page, which currently has two sentences that are not factually accurate. As I am associated with the company that makes Concerta(R), I'm starting this Concerta Talk page to declare my interest in providing this factual information, per Wiki COI guidelines.

I would like to provide information that is consistent with information on the Concerta(R)FDA-approved product label and the FDA website regarding our product. Below is the information I would like to provide for the page, as the last two sentences currently on the page do not accurately define the development and formulation of Concerta(R) according to information on the product label and FDA website. While I know the following is not particularly elegant, more importantly it is completely accurate and referenced/supported by FDA approved information.

Concerta(R) was specifically designed to be the first, once-daily methylphenidate to eliminate the need for multiple doses during the day. It is approved for the treatment of Attention Deficit Hyperactivity Disorder.

The tablet has an outer coat of medication. The remaining medication is contained in a non-absorbable shell that releases medication at a controlled rate. The tablet shell, along with the insoluble core components, is eliminated from the body and should not be taken by patients with severe gastrointestinal narrowing; patients should not be concerned if they occasionally notice in their stool something that looks like a tablet.

Tricia Geoghegan (talk) 18:20, 20 February 2009 (UTC)Tricia Geoghegan, Communications Manager, McNeil Pediatrics[reply]